Capricor Therapeutics, Inc. (CAPR) Stock Price & Analysis
Capricor Therapeutics, Inc. (CAPR) fell 0.66% to USD 19.7 as of July 25, 2026 at 06:54 UTC, according to Nexqual real-time market data.
CAPR last closed at USD 19.83; the session ranged USD 18.31–20.18 on volume of 2,458,714 shares. Market capitalization is $1.14B, with a 52-week range of USD 4.3–40.37 (NMS). Source: Nexqual, July 25, 2026 at 06:54 UTC.
Key Statistics (as of July 25, 2026 at 06:54 UTC)
| Price | USD 19.7 |
|---|---|
| Change | ▼ 0.66% (down) |
| Previous Close | USD 19.83 |
| Open | USD 19.77 |
| Day Range | USD 18.31 – 20.18 |
| 52-Week Range | USD 4.3 – 40.37 |
| Volume | 2,458,714 shares |
| Market Cap | $1.14B |
| Exchange | NMS |
Technical Analysis (CAPR)
Nexqual's technical model rates CAPR "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:54 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.37 (neutral) |
| vs SMA50 | Below (USD 25.46) |
| MACD | -1.97 (negative) |
Analyst Ratings (CAPR)
Wall Street analysts rate CAPR "Strong Buy" based on 10 analysts, with a mean price target of USD 53.6 (range USD 38–63), per Nexqual as of July 25, 2026 at 06:54 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 53.6 |
| High Target | USD 63 |
| Low Target | USD 38 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (CAPR)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.59 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.62 vs est -0.55 ▼ miss |
| 2025-09-30 | USD -0.54 vs est -0.54 ▲ beat |
| 2025-06-30 | USD -0.57 vs est -0.48 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
Financials & Fundamentals (CAPR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -56.40% |
| Debt / Equity | 5.31 |
| Current Ratio | 8.42 |
| Total Cash | $278.61M |
| Total Debt | $14.78M |
| Free Cash Flow | $-70.47M |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
Financial Health Score (CAPR)
Nexqual rates Capricor Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:54 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $279M cash vs $15M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$93M |
| Efficiency | Critical — ROE -56%, ROA -31.2% |
Ownership (CAPR)
| Insider Ownership | +9.47% |
|---|---|
| Institutional Ownership | +59.65% |
| Shares Outstanding | 57.91M |
| Float | 48.55M |
| Short % of Float | +29.71% |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
Leadership (CAPR)
Capricor Therapeutics, Inc. is led by Linda Marbán (age 62), Co-Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 06:54 UTC.
| Co-Founder, President, CEO & Director | Linda Marbán (age 62) |
|---|---|
| Executive Chairman of the Board | Frank Isaac Litvack FACC (age 69) |
| CFO & Corporate Treasurer | Anthony J. Bergmann (age 39) |
| Chief Operating & Science Officer | Kristi A. H. Elliott |
| Senior Vice President of Quality Control, Research & Product Development | Minghao Sun |
Major Backers & Investors (CAPR)
Notable institutional backers of Capricor Therapeutics, Inc. include Suvretta Capital Management, LLC, Tang Capital Management, LLC, RA Capital Management, L.P., according to Nexqual as of July 25, 2026 at 06:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 6.59% |
| Tang Capital Management, LLC | 5.87% |
| RA Capital Management, L.P. | 2.6% |
| Fidelity | 2.13% |
| Jones Hill Capital LP | 1.57% |
| Goldman Sachs | 1.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.32% |
| State Street | 7.52% |
| Vanguard Group | 7.25% |
| Geode Capital | 1.93% |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
From Capricor Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Biologics License Application : In late 2024, we completed our submission of a BLA to the FDA seeking approval of Deramiocel for the treatment of Duchenne muscular dystrophy.
- Following a Type A meeting with the FDA in August 2025, we aligned with the Agency on a regulatory path forward to address the CRL, including the submission of additional clinical data from the Phase 3 HOPE-3 trial.
- Exosome Platform: Engineered Exosome-Based Vaccines : The StealthX™ vaccine is a proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
- In mid-2025, the FDA completed its Pre-License Inspection ("PLI") of this facility in connection with our Biologics License Application for Deramiocel.
Partnerships
- In addition, Capricor may terminate for any reason upon 60 days' written notice. ​ Cedars-Sinai Medical Center License Agreements License Agreement for CDCs On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the "Original CSMC License Agreement"), for certain intellectual property related to its CDC technology.
- License Agreement for Exosomes On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the "Exosomes License Agreement"), for certain intellectual property rights related to CDC-derived exosomes technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBRX | Moleculin Biotech, Inc. | USD 2.12 | ▲ 0.95% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.52 | ▼ 10.59% |
| AYTU | Aytu BioPharma, Inc. | USD 2.16 | ▲ 0% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:54 UTC. This page is informational and not investment advice.